Elsevier

Schizophrenia Research

Volume 190, December 2017, Pages 60-62
Schizophrenia Research

Early onset of cardiometabolic risk factor profiles in drug naïve adolescents and young adults with first-episode schizophrenia

https://doi.org/10.1016/j.schres.2017.03.004Get rights and content

Abstract

Objective and method

We performed a case-control study, which included antipsychotic-naïve first-episode schizophrenia (FES) of adolescents and young adults and general population controls, to investigate the early-onset cardiometabolic risk factors in FES.

Results

FES had more frequent lower HDL-C when compared to controls. However, the distribution of BMI and the frequency of hypercholesterolemia, elevated LDL-C, hypertriglyceridemia in FES were not significantly different to controls.

Conclusions

The results indicated that abnormal HDL-C might be an early-onset event in drug-naïve FES of adolescents and young adults who are unlikely to have other cardiometabolic risks.

Section snippets

Role of funding source

This work was supported by Natural Science Training Project by Xinxiang Medical University 2013ZD107 (to DZ), Program for Science&Technology Innovation Talents in Universities of Henan Province, China 14HASTIT034 (to YZ) and Undergraduate Innovation Project by Ministry of Education of China 201310472020, 201310472003, 201310472011. Partly supported by the support project for the Disciplinary Group of Psychology and Neuroscience, Xinxiang Medical University 2016PN-KFKT-30 (to YZ).

Contributors

YZ, DZ and YL designed studies, performed the experiments, wrote manuscript. RZ designed studies and contributed to revising manuscript. YF, YL, TC, CN, GD, YJ, XZ performed the experiments and contributed to revise manuscript. YC and XW contributed to revise manuscript. All authors participated in revising the manuscript and the final approval of the manuscript.

Conflict of interest

All other authors declare that they have no conflicts of interest.

Acknowledgements

The authors thank Dr. Dost Öngür (Harvard Medical School, McLean Hospital) for his suggestions on study concept and design. The authors also thank MD. Tuna Hasoglu (McLean Hospital) revised the language of the manuscript.

References (7)

There are more references available in the full text version of this article.

Cited by (14)

  • A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients

    2020, European Neuropsychopharmacology
    Citation Excerpt :

    Furthermore, our results suggest that if the weight gain is controlled, we can reduce lipid and glycaemic abnormalities secondarily due to his correlation. Despite of this, recent studies have proposed that cardiometabolic risk factors and other metabolic abnormalities are present early in the illness (Pillinger et al., 2017; Zhai et al., 2017; Correl et al., 2014), even regardless of antipsychotic exposure (Pillinger et al., 2017; Jensen et al., 2017). These evidences suggest that the metabolic alterations seen in psychosis have a multi-factor etiology, including not only the effect of antipsychotic treatment but also many other clinical, sociodemographic and environmental elements, such as sedentary lifestyle and eating habits.

View all citing articles on Scopus
1

Both authors contributed equally to this work.

View full text